Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

Authors: Jiménez-Fonseca, P., Sastre, J., García-Alfonso, P., Gómez-España, M.A., Salud, A., Gil, S., Rivera, F., Reina, J.J., Quintero, G., Valladares-Ayerbes, M., Safont, M.J., La Casta, A., Robles-Díaz, L., García-Paredes, B., López López, R., Guillot, M., Gallego, J., Alonso-Orduña, V., Diaz-Rubio, E., Aranda, E.

Source: Clinical colorectal cancer. 22(2):222-230

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100190916801.0x000001&indx=1&recIds=ETOCvdc_100190916801.0x000001

A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients

Authors: Toledano-Fonseca, M., Gómez-España, M.A., Élez, E., Grávalos, C., García-Alfonso, P., Rodríguez, R., Losa, F., Alés Díaz, I., Graña, B., Valladares-Ayerbes, M., García-Ortiz, M.V., Polo, E., Salgado, M., Rivera, F., Safont, M.J., Salud, A., Ruiz-Casado, A., Tabernero, J.M., Riesco, M.C., Rodríguez-Ariza, A., Aranda, E.

Source: In Biomedicine & Pharmacotherapy March 2023 159

Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and

Authors: Viéitez, J.M., Jiménez, P., Aguilar, E. Aranda, Gómez, A., Gil Calle, S., Salud, A., Valladares, M., Graña, B., García-Alfonso, P., Rivera, F., Quintero, G., Reina, J.J., González Flores, E., Salgado, M., Grande, E., Guillén, C., Garcia Carbonero, R., Flor, M.J., Safont, M.J., La Casta, A., Arévalo, S., Sastre, J., López López, R., Manzano, H., Guillot, M., Hernández Yagüe, X., Arrivi, A., Falcó, E., Gallego, J., Escudero, P., Cabezas, I., Juárez, A., Gálvez, E., Grávalos, C., Robles, L., Polo, E., Dueñas, R., Campos, J.M., Albert, A., Salinas, P., Montagut, C., Provencio, M., Ruiz Casado, A., Muñoz, J., Gil Raga, M., Chilet, M.R., González González, F.J., Massutí, B., López, A., Aparicio, J., Marín, M., Alfaro, J., Zanui, M., Gutiérrez Abad, D., García Tapiador, A.M., García-Girón, C., Molina Saera, J., Torres Sánchez, E., López, I., Bosch, C., Valero, J., Martínez de Prado, P., Cano, M.T., Reina-Zoilo, J.J., Salud-Salvia, A., Robles-Díaz, L., Gil, S., Asensio-Martínez, E., García-Paredes, B., López, R.L., Valladares-Ayerbes, M., Aranda, E., Díaz-Rubio, E.

Source: In ESMO Open April 2021 6(2)

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

Authors: Vidal, J., Bellosillo, B., Santos Vivas, C., García-Alfonso, P., Carrato, A., Cano, M.T., García-Carbonero, R., Élez, E., Losa, F., Massutí, B., Valladares-Ayerbes, M. ^*, Viéitez, J.M. ^*, Manzano, J.L., Azuara, D., Gallego, J., Pairet, S., Capellá, G., Salazar, R., Tabernero, J., Aranda, E., Montagut, C. ^*

Source: In Annals of Oncology March 2019 30(3):439-446

Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial

Authors: Abad, A., Martínez-Balibrea, E. ^*, Viéitez, J.M., Alonso-Orduña, V., García Alfonso, P., Manzano, J.L., Massutí, B., Benavides, M., Carrato, A., Zanui, M., Gallego, J., Grávalos, C., Conde, V., Provencio, M., Valladares-Ayerbes, M., Salazar, R., Sastre, J., Montagut, C., Rivera, F., Aranda, E.

Source: In Annals of Oncology February 2018 29(2):439-444

Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain

Authors: Feliu, J., Díez de Corcuera, I., Manzano, J. L., Valladares-Ayerbes, M., Alcaide, J., García García, T., Vera, R., Sastre, J.

Source: CLINICAL AND TRANSLATIONAL ONCOLOGY. 19(4):498-507

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN383250296&indx=1&recIds=ETOCRN383250296

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings

Authors: Andel, J., Balcke, P., Benedicic, B., Eisterer, W., Fridrik, M., Jagdt, B., Keil, F., Kretschmer, A., Krippl, P., Oexle, H., Pecherstorfer, M., Samonigg, H., Schmid, M., Thaler, J., Tinchon, C., Weiss, H., Arts, J., De Man, M., Demolin, G., Janssens, J., Polus, M., Benczikova, B., Melichar, B., Prausova, J., Vitek, P., Andersen, F.Z., Jensen, B.B., Keldsen, N., Østerlind, K., Vistisen, K., Elme, A., Magi, A., Ojamaa, K., Ristamäki, R., Salminen, T., Ben Abdelghani, M., Bouche, O., Borg, C., Bouhier-Leporrier, K., Breysacher, G., Chone, L., Clavero Fabri, M.-C., Deplanque, G., Desseigne, F., Dourthe, L.-M., Ezenfis, J., Faroux, R., François, E., Garnier, C., Gaspard, M.-H., Hebbar, M., Illory, J.F., Kaminsky, M.-C., Lecomte, T., Legoux, J.-L., Levache, B., Lobry, C., Lotz, J.-P., Mabro, M., Manet-Lacombe, S., Manfredi, S., Matysiak Budnik, T., Miglianico, L., Mineur, L., Moullet, I., Naman, H., Nouyrigat, P., Oziel-Taieb, S., Perrier, H., Pezet, D., Philip, J., Pottier, V., Porneuf, M., Ramdani, M., Re, D., Rinaldi, Y., Spaeth, D., Taieb, J., Terrebonne, E., Texereau, P., Thirot Bidault, A., Tournigand, C., Tubiana-Mathieu, N., Vantelon, J.-M., Viret, F., Ychou, M., Bangerter, M., Bertram, M.E., Bohnsteen, B., Brinkmann, L., Caca, K., Constantin, C., Cordes, H.-J., Dietrich, G., Eggert, J., Engel, E., Fahlke, J., Fensterer, H., Florschütz, A., Folprecht, G., Forstbauer, H., Freier, W., Freund, M., Frickhofen, N., Gäbele, E., Geißler, M., Gieseler, F., Göhler, T., Graeven, U., Groschek, M., Grundeis, M., Hacker, U., Hagen, V., Hebart, H.F., Hegewisch-Becker, S., Heike, M., Herrmann, T., Hildebrandt, B., Höffkes, H.-G., Hübner, G., Hübner, J., Kettner, E., Kneba, M., Kohnke, J.W., Kojouharoff, G., König, C., Kretzschmar, A., Kröning, H., Kürner, K., Lammert, F., Lerchenmüller, C., Lück, A., Meiler, J., Mergenthaler, H.-G., Müller, L., Müller-Naendrup, C., Nusch, A., Papke, J., Porschen, R., Rädle, J., Reddemann, C., Ridwelski, K., Riera-Knorrenschild, J., Rudi, J., Schmalenberger, A., Schimanski, C.-C., Schlegel, F., Schlichting, C., Schmidt, P., Schmiegel, W., Schmitz, S., Schulze-Bergkamen, H., Schwaner, I., Schwarzer, A., Schwerdtfeger, M., Selbach, J., Sieber, M., Siebler, J., Staib, P., Stauch, M., Steffens, C.-C., Stübs, P., Tischendorf, J., Trarbach, T., Tummes, D., Valdix, A.-R., Vogel, A., Von Wichert, G.P.L., Walther, M., Welslau, W., Wilhelm, G., Wobster, H., Wolf, T., Zeigenhagen, N., Zomorodbaksch, B., Batman, E., Bloemendal, H.J., Kehrer, D.F.S., Guren, T., Indrebø, G., Kersten, C., Soerbye, H., Fragoso, M., Fragoso, R., Mellidez, J.C., Sa, A., Aljobran, A., Darwish, T., Alonso-Orduna, V., Aparicio, J., Aranda, E., Bosch, C., Galan-Brotons, A., Busquier Hernandez, I., Camara, J.C., Campos Cervera, J.M., Carlos Garcia Giron, C., Del Prado, P.M., Donnay, O., Escudero, P., Falco, E., Gallego Plazas, J., Garcia Alfonso, P., Gonzalez Flores, E., Gravalos, C., Guardeno, R., Juárez, A., Lopez Ladron, A., Losa Gaspa, F., MªVicent Vergé, J., Marcuello Gaspar, E., Massuti Sureda, B., Molina, J., Montero, I.C., Muñoa, A.L., Naranjo, M.B., Oruezabal Moreno, M.J., Pachón Olmos, V., Pericay, C., Reina Zoilo, J.J., Rivera, F., Ruiz Casado, A., Safont, M.J., Salud Salvia, A., Tobena, M., Toral, J.C., Valenti, V., Valladares Ayerbes, M., Vieitez, J.M., Vera, R., Berglund, A., Fernebro, E., Hess-Umbricht, V., Pless, M., Popescu, R., Winterhalder, R., Kubicka, S. ^*, Greil, R., André, T., Bennouna, J., Sastre, J., Van Cutsem, E., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Makrutzki, M., Arnold, D.

Source: In Annals of Oncology September 2013 24(9):2342-2349

Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

Authors: Taieb, J., Rivera, F., Siena, S., Karthaus, M., Valladares-Ayerbes, M., Gallego, J., Geissler, M., Koukakis, R., Demonty, G., Peeters, M.

Source: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 144(4):795-797

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN387841993&indx=1&recIds=ETOCRN387841993

Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer

Authors: Eatock, M.M. ^*, Tebbutt, N.C., Bampton, C.L., Strickland, A.H., Valladares-Ayerbes, M., Swieboda-Sadlej, A., Van Cutsem, E., Nanayakkara, N., Sun, Y.-N., Zhong, Z.D., Bass, M.B., Adewoye, A.H., Bodoky, G.

Source: In Annals of Oncology March 2013 24(3):710-718

Current controversies in the management of metastatic colorectal cancer

Authors: Vera, R., Alonso, V., Gállego, J., González, E. n., Guillén-Ponce, C., Pericay, C., Rivera, F., Safont, M. J., Valladares-Ayerbes, M.

Source: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 76(4):659-677

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN372888684&indx=1&recIds=ETOCRN372888684

Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in 'suboptimal' patients with advanced gastric cancer (AGC). TTD 08-02

Authors: Rivera, F., Massutí, B., Salcedo, M., Sastre, J., Martínez Galán, J., Valladares-Ayerbes, M., Serrano, R., Paredes, M. L., Manzano, J. L., Galán, M.

Source: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 75(2):319-324

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN366333676&indx=1&recIds=ETOCRN366333676

Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study)

Authors: Aranda, E. ^*, Manzano, J.L., Rivera, F., Galán, M., Valladares-Ayerbes, M., Pericay, C., Safont, M.J., Mendez, M.J., Irigoyen, A., Arrivi, A., Sastre, J., Díaz-Rubio, E.

Source: In Annals of Oncology July 2012 23(7):1919-1925

585PPOLAF study: Efficacy and safety of FOLFIRI/aflibercept in a phase II trial in patients with metastatic colorectal cancer: Results of plasmatic prognostic and predictive markers

Authors: Fernandez, M E Elez, Gómez-España, M A, Grávalos, C, García-Alfonso, P, Rodríguez, B, Losa, F, Ales-Diaz, I C, Suarez, B Graña, Toledano, M, Valladares-Ayerbes, M, Marques, E Polo, Fernandez, M Salgado, de Castro, E Martínez, Raga, M Gil, Salvia, M A Salud, Ruiz-Casado, A, Rodríguez-Ariza, A, Aguilar, E Aranda

Source: Annals of oncology. 30(5)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100097989928.0x000001&indx=1&recIds=ETOCvdc_100097989928.0x000001

531PDSequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first-line (1L): PERSEIDA study

Authors: Valladares-Ayerbes, M, García-Alfonso, P, Luengo, J Muñoz, Cáceres, P Pimentel, Viéitez, J M, Cruz-Hernández, J J, Llanos, M, Girón, C Garcia, Cirera, L, Vila, A Lloansí

Source: Annals of oncology. 30(5)

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100097989659.0x000001&indx=1&recIds=ETOCvdc_100097989659.0x000001

Gemcitabine and Capecitabine as Third- or Later-line Therapy for Refractory Advanced Colorectal Cancer: A Retrospective Study

Authors: Salgado, M., Reboredo, M., Mendez, J.C., Quintero, G., Pellon, M.L., Romero, C., Jorge, M., Montes, A.F., Valladares-Ayerbes, M., Ramos, M.

Source: ANTICANCER RESEARCH. 33(9):4089-4096

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN339601341&indx=1&recIds=ETOCRN339601341

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study

Authors: Rao, S., Starling, N., Cunningham, D. ^*, Sumpter, K., Gilligan, D., Ruhstaller, T., Valladares-Ayerbes, M., Wilke, H., Archer, C., Kurek, R., Beadman, C., Oates, J.

Source: In Annals of Oncology November 2010 21(11):2213-2219

Searching for Hif1-α interacting proteins in renal cell carcinoma

Authors: Medina Villaamil, V., Aparicio Gallego, G., Santamarina Caínzos, I., Valladares-Ayerbes, M., Antón Aparicio, L. M.

Source: CLINICAL AND TRANSLATIONAL ONCOLOGY. 14(9):698-708

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN318975095&indx=1&recIds=ETOCRN318975095

Oxaliplatin in Combination With Infusional 5-Fluorouracil as First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Phase II Study of the Spanish Cooperative Group for the Treatment of Digestive Tumors

Authors: Benavides, M., Pericay, C., Valladares-Ayerbes, M., Gil-Calle, S., Massutí, B., Aparicio, J., Dueñas, R., González-Flores, E., Carrato, A., Marcuello, E.

Source: CLINICAL COLORECTAL CANCER. 11(3):200-206

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN317606319&indx=1&recIds=ETOCRN317606319

First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study

Authors: Sastre, J., Gravalos, C., Rivera, F., Massuti, B., Valladares-Ayerbes, M., Marcuello, E., Manzano, J.L., Benavides, M., Hidalgo, M., Diaz-Rubio, E.

Source: ONCOLOGIST -MIAMISBURG-. 17(3):339-345

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN310535071&indx=1&recIds=ETOCRN310535071

Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer

Authors: Valladares-Ayerbes, M., Blanco, M., Haz, M., Medina, V., Iglesias-Diaz, P., Lorenzo-Patino, M.J., Reboredo, M., Santamarina, I., Figueroa, A., Anton-Aparicio, L.M.

Source: INTERNATIONAL JOURNAL OF ONCOLOGY. 39(5):1253-1264

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN298723783&indx=1&recIds=ETOCRN298723783